199 related articles for article (PubMed ID: 31190621)
1. Effects of
Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL
Pharmacogenomics; 2019 Jun; 20(8):571-580. PubMed ID: 31190621
[No Abstract] [Full Text] [Related]
2. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
3. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
[TBL] [Abstract][Full Text] [Related]
6. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN; Nguyen AT; Li L; Desta Z; Henry NL; Hayes DF; Wolff AC; Stearns V; Storniolo AM; Flockhart DA;
J Clin Pharmacol; 2012 Dec; 52(12):1852-60. PubMed ID: 22174434
[TBL] [Abstract][Full Text] [Related]
7. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
11. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Hertz DL; Speth KA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Breast Cancer Res Treat; 2017 Oct; 165(3):659-668. PubMed ID: 28643023
[TBL] [Abstract][Full Text] [Related]
12. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
[TBL] [Abstract][Full Text] [Related]
13. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
[TBL] [Abstract][Full Text] [Related]
14. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
15. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of exemestane.
Lintermans A; Neven P; Paridaens R
Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM
Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243
[TBL] [Abstract][Full Text] [Related]
18. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
[TBL] [Abstract][Full Text] [Related]
19.
Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
[TBL] [Abstract][Full Text] [Related]
20. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
